179062-06-7

Basic information

• Product Name: 4,5-DIAMINO-2-FLUOROBENZOTRIFLUORID
• Synonyms: 4,5-DIAMINO-2-FLUOROBENZOTRIFLUORID;4-Fluoro-5-(trifluoromethyl)phenylene-1,2-diamine;4-Fluoro-5-(trifluoromethyl)benzene-1,2-diamine, 1,2-Diamino-4-fluoro-5-(trifluoromethyl)benzene;4-Fluoro-5-(trifluoroMethyl)benzene-1,2-diaMine;4,5-Diamino-2-fluorobenzotrifluoride97%;4-fluoro-5-(trifluoromethyl)-1,2-diaminobenzene
• CAS NO: 179062-06-7
• Molecular Formula: C₇H₆F₄N₂
• Molecular Weight: 194.1295528
• Mol File: 179062-06-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 4,5-DIAMINO-2-FLUOROBENZOTRIFLUORID(CAS DataBase Reference)
• NIST Chemistry Reference: 4,5-DIAMINO-2-FLUOROBENZOTRIFLUORID(179062-06-7)
• EPA Substance Registry System: 4,5-DIAMINO-2-FLUOROBENZOTRIFLUORID(179062-06-7)

Safety Data

• Hazardous Substances Data: 179062-06-7(Hazardous Substances Data)

Usage

Uses

3,4-Diamino-6-fluorobenzotrifluoride is a reagent used in the synthesis of orally efficacious benzimidazoles as melanin-concentrating hormone receptor 1 antagonists.

Upstream product

• 143151-01-3 4-fluoro-2-nitro-5-(trifluoromethyl)acetanilide 
• 2357-47-3 4-Fluoro-3-trifluoromethylaniline 
• 2145-38-2 4-fluoro-3-(trifluoromethyl)acetanilide 
• 1026828-94-3 N-(5-fluoro-2-nitro-4-trifluoromethyl-phenyl)-acetamide 
• 1026932-27-3 N-(3-fluoro-4-trifluoromethyl-phenyl)-acetamide 
• 428871-73-2 5-fluoro-2-nitro-4-(trifluoromethyl)aniline 
• 179062-05-6 4-fluoro-2-nitro-5-trifluoromethyl-aniline 

Downstream Products

• 846049-68-1 4-[(4-bromo-phenyl)-(5-fluoro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-methylene]-piperidine-1-carboxylic acid tert-butyl ester 
• 846049-70-5 1-(4-bromo-phenyl)-1-(5-fluoro-6-trifluoromethyl-1H-benzoimidazol-2-yl)-6-aza-spiro[2.5]octane-6-carboxylic acid tert-butyl ester 
• 904283-21-2 2-[3-(1-benzyl-piperidin-4-yl)-3-(4-bromo-phenyl)-propyl]-5-fluoro-6-trifluoromethyl-1H-benzoimidazole 

Relevant articles and documents

2-Substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders

The present invention discloses compounds of formula I wherein Ar, X, R1 and R11 are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In

Synthesis and structure-activity relationships of substituted 1,4- dihydroquinoxaline-2,3-diones: Antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors

A series of mono-, di-, tri-, and tetrasubstituted 1,4- dihydroquinoxaline-2,3-diones (QXs) were synthesized and evaluated as antagonists at N-methyl-D-aspartate (NMDA)/glycine sites and α-amino-3- hydroxy-5-methylisoxazole-4-propionic acid-preferring non-NMDA receptors. Antagonist potencies were measured by electrical assays in Xenopus oocytes expressing rat whole brain poly(A)+ RNA. Trisubstituted QXs 17a (ACEA 1021), 17b (ACEA 1031), 24a, and 27, containing a nitro group in the 5 position and halogen in the 6 and 7 positions, displayed high potency (K(b) ~ 6-8 nM) at the glycine site, moderate potency at non-NMDA receptors (K(b) = 0.9-1.5 μM), and the highest (120-250-fold) selectivity in favor of glycine site antagonism over non-NMDA receptors. Tetrasubstituted QXs 17d,e were more than 100-fold weaker glycine site antagonists than the corresponding trisubstituted QXs with F being better tolerated than Cl as a substituent at the 8 position. Di- and monosubstituted QXs showed progressively weaker antagonism compared to trisubstituted analogues. For example, removal of the 5-nitro group of 17a results in a ~100-fold decrease in potency (10a,b,z), while removal of both halogens from 17a results in a ~3000-fold decrease in potency (10v). In terms of steady-state inhibition, most QX substitution patterns favor antagonism at NMDA/glycine sites over antagonism at non-NMDA receptors. Among the QXs tested, only 17i was slightly selective for non- NMDA receptors.